11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and...
Pearce IP BioBlast w/e 15 April 2022
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Interlocutory Injunction To Restrain Further Threats Of Patent Infringement Proceedings Granted In Car Park Scrap
In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA...
Our 2022 Client Survey Results are in!
Thank you to all our clients who participated in the inaugural 2022 Pearce IP “We Hear You” survey. The responses we...
Pearce IP BioBlast w/e 8 April 2022
31 March 22 | Fresenius Kabi announced that it has bought a majority stake (55%) in mAbxience, a company specialising...
Full Court confirms expert evidence out of fingolimod trial
Novartis AG v Pharmacor Pty Ltd [2022] FCAFC 58 Date:Court:Judges:4 April 2022Full Federal Court of...
Patent litigation in Australia just got a little cheaper
Full Court confirms duplicative expert evidence legitimately excluded on discretionary grounds
The Full Court’s refusal of leave to appeal today in Novartis AG v Pharmacor Pty Limited [2022] FCAFC 58 is good news...
Australian Government commits to claim damages from originator pharmaceutical companies where generic entry is unduly delayed
In its 2022-23 Budget, the Coalition Government has stated that it will continue to fund litigation against originator...
Pearce IP BioBlast w/e 1 April 2022
28 Mar 22 | Aurobindo announced that it will acquire certain business assets from Veritaz (the supplier of branded...
AU Budget 22-23: Highlights for Health, Pharma/Biopharma, Life Sciences & Agribusiness
In the Coalition Government’s Budget for the financial year 2022-23, it sets out the investments that it would make...
Pearce IP BioBlast w/e 25 March 2022
19 Mar 22 | US | Amgen and Pfizer settled their pegfilgrastim (Neulasta®) dispute Amgen Inc v Hospira Inc (D. Del.,...
Full Federal Court clarifies rules for patent term extensions – Part 2
Commissioner of Patents v Ono Pharmaceutical Co. Ltd & Anr [2022] FCAFC 39 Date:Court:Judges:18 March 2022Full...
Full Federal Court clarifies rules for patent term extensions – Part 1
Merck Sharp & Dohme & Anor v Sandoz Pty Ltd [2022] FCAFC 40 Date:Court:Judges:18 March 2022Full Federal Court...
Pearce IP BioBlast w/e 18 March 2022
14 Mar 22 | OcyonBio announced that it has entered into a manufacturing and operations agreement with Biosimilar...
Pharmacia’s Dynastat patent valid, imminent patent expiry no reason to avoid injunction
Introduction Pharmacia LLC and Pfizer Australia Pty Ltd (together, Pharmacia) have partially succeeded at first...
High Court Puts The Brakes On Damages Recovery During Patent Term Extension
Introduction The decision of the High Court in H. Lundbeck A/S v Sandoz Pty Ltd [2022] HCA 4 (Lundbeck) last week...
Breaking News – Full Court strikes down two PTEs
A PTE must be based on the earliest approved product even when it is a competitor product.
On 18 March 2022, the Full Court gave highly awaited judgments in two cases[1] concerning the validity of patent term...